DASH vs PRLD · P/E 76, rev $13.72B vs rev $6.5M
DoorDash, Inc. Class A Common Stock (DASH) versus Prelude Therapeutics Inc (PRLD) — a side-by-side from cached financials, not a winner call.
DoorDash, Inc. Class A Common Stock (DASH) is a internet retail company listed on US.
Prelude Therapeutics Inc (PRLD) is a biotechnology company listed on NASDAQ.
Latest reported DASH revenue for 2025-12-31 was $13.72B. Net income was $935.0M. Revenue was up 27.9% from 2024-12-31 to 2025-12-31. DASH currently screens at market cap $69.41B and trailing P/E 75.9.
Latest reported PRLD revenue for 2025-09-30 was $6.5M. Net income was -$83.0M. Revenue was up 116.7% from 2024-09-30 to 2025-09-30. PRLD currently screens at market cap $346.5M.
DASH currently screens at market cap $69.41B and trailing P/E 75.9. PRLD currently screens at market cap $346.5M.
Not investment advice. Open the DASH and PRLD stock pages for the full models.
Not investment advice.